Overcoming current bioprocessing limitations
The industrial production of biologics often relies on large-scale cell culture using mammalian cells as the preferred expression system. Traditional stirred tank bioreactors, while widely used, present challenges in adapting adherent cell lines to suspension culture. Many of these cell lines remain adherent, necessitating the use of adherent-compatible technologies that are difficult to scale efficiently. Traditional manufacturing platforms like multilayer culture dishes and roller bottles require scale-out rather than scale-up, limiting production efficiency. Microcarriers offer some solutions but introduce their own complexities, such as cumbersome cell attachment and detachment protocols.
The new generation scale-X™ structured fixed-bed bioreactor addresses these issues by integrating structuring elements within the bed, ensuring a consistently homogeneous environment across scales.
This article explores the key principles behind scale-X™ technology and its potential to overcome current bioprocessing limitations.
Interested?
Download the paper to explore the basic design principles that achieve higher productivity for both adherent and suspension cells.